News & Events :: Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics, Inc. News: Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Learn More

Recent NewsView All News

Oct 11, 2024 9:15am EDT

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Oct 9, 2024 9:15am EDT

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Recent Events View All Events

Oct 8 – Oct 12, 2024

29th Annual Congress of the World Muscle Society (WMS 2024)

Sep 24, 2024 8:30 am EDT

Duchenne Muscular Dystrophy Program Update

View All Events

Latest Presentation View All Presentations

Oct 9, 2024

Investor Presentation - October 2024

View All Presentations

Email Alerts

Sign up for email alerts for Press Releases & SEC Filings